Previous 10 | Next 10 |
Coronavirus Pandemic Tianjin CanSino Biologics (HK: 6185) published positive results from a China Phase I trial of its COVID-19 vaccine in the prestigious British journal, The Lancet. In the study, the Ad5 vectored COVID-19 vaccine was immunogenic at 28 days post-vaccination with only mild...
You've no doubt thought to yourself, "If only I'd have done [fill in the blank] back then." It's easy to see in retrospect what would have been a great move to make. Buying Moderna (NASDAQ: MRNA) at its initial public offering (IPO) is a great example. While the overall stock mark...
Real Estate Weekly Outlook U.S. equity markets surged this week, buoyed by news of positive clinical trial results from Moderna ( MRNA ) and Inovio Pharmaceuticals ( INO ) and on renewed hopes of a V-shaped economic recovery as most states and countries around the world have begun the ...
This time we will present our readers with the Eaton Vance Tax-Managed Global Diversified Equity Income Fund ( EXG ), which was incorporated in February 2007. It is a closed-ended fund that is primarily focused on global dividend-paying companies while using the strategy of writing index cal...
NEW ORLEANS , May 22, 2020 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advis...
"We don't have an analytical advantage, we just look in the right place." - Seth Klarman The Health Care Select Sector SPDR ETF (XLV) is putting the "V" in XLV. The ETF has recovered over 35% since the March 23 lows and is now barely negative on the year, down only 0.3%, including dividend...
With a significant portion of the world still in lockdown due to the COVID-19 pandemic, many investors are anxious about how soon a vaccine can be developed to combat the coronavirus. Currently, one of the most promising candidates for this challenge is Moderna 's (NASDAQ: MRNA) mRNA-1273 vac...
Stocks dipped on Friday as tensions between China and the U.S. offset the increasing optimism around a potential coronavirus vaccine. The Dow Jones Industrials lost another 139.54 points to move into the final session before a long weekend at 24,334.58. The S&P 500 docked 10.19 p...
U.S. stock futures rose slightly early Friday as Wall Street wrapped up a winning week. Futures for Dow Jones Industrials advanced 45 points, or 0.2%, early Friday to 24,421. Futures for the S&P 500 sailed 6.5 points, or 0.4%, higher at 2,943.50. Futures for the NASDAQ Composit...
"Having looked at the data," it is "quite promising", NIH's Dr. Anthony Fauci said in an interview on NPR of Moderna's (NASDAQ: MRNA ) new efforts and it's Phase 1 trial. More news on: Moderna, Inc., SPDR S&P 500 Trust ETF, News on the U.S. economy, News on ETFs, Read m...
News, Short Squeeze, Breakout and More Instantly...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
2024-04-26 04:50:00 ET Moderna (NASDAQ: MRNA) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dollars in sales. But as demand for the vaccine declined, Moderna stock followed. Investors are worried...
GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a...